JP4443043B2 - 半合成エクテイナシジン - Google Patents

半合成エクテイナシジン Download PDF

Info

Publication number
JP4443043B2
JP4443043B2 JP2000542009A JP2000542009A JP4443043B2 JP 4443043 B2 JP4443043 B2 JP 4443043B2 JP 2000542009 A JP2000542009 A JP 2000542009A JP 2000542009 A JP2000542009 A JP 2000542009A JP 4443043 B2 JP4443043 B2 JP 4443043B2
Authority
JP
Japan
Prior art keywords
mammalian
pharmaceutical composition
mmol
compound
etainacidin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2000542009A
Other languages
English (en)
Japanese (ja)
Other versions
JP2002510633A (ja
JP2002510633A5 (enExample
Inventor
ラインハート、ケネス、エル
モラルス、ホセ、ジェイ
Original Assignee
ザ ボード オブ トラスティーズ オブ ザ ユニバーシテイ オブ イリノイ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ザ ボード オブ トラスティーズ オブ ザ ユニバーシテイ オブ イリノイ filed Critical ザ ボード オブ トラスティーズ オブ ザ ユニバーシテイ オブ イリノイ
Publication of JP2002510633A publication Critical patent/JP2002510633A/ja
Publication of JP2002510633A5 publication Critical patent/JP2002510633A5/ja
Application granted granted Critical
Publication of JP4443043B2 publication Critical patent/JP4443043B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D515/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D515/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains four or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Dental Preparations (AREA)
  • Saccharide Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Separation Of Suspended Particles By Flocculating Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Furan Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
JP2000542009A 1998-04-06 1999-04-05 半合成エクテイナシジン Expired - Fee Related JP4443043B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US8080298P 1998-04-06 1998-04-06
US60/080,802 1998-04-06
PCT/US1999/007471 WO1999051238A1 (en) 1998-04-06 1999-04-05 Semi-synthetic ecteinascidins

Publications (3)

Publication Number Publication Date
JP2002510633A JP2002510633A (ja) 2002-04-09
JP2002510633A5 JP2002510633A5 (enExample) 2006-05-25
JP4443043B2 true JP4443043B2 (ja) 2010-03-31

Family

ID=22159716

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2000542009A Expired - Fee Related JP4443043B2 (ja) 1998-04-06 1999-04-05 半合成エクテイナシジン

Country Status (27)

Country Link
US (1) US6124293A (enExample)
EP (2) EP1876180A3 (enExample)
JP (1) JP4443043B2 (enExample)
KR (1) KR100603219B1 (enExample)
CN (1) CN1157189C (enExample)
AT (1) ATE370148T1 (enExample)
AU (1) AU758100B2 (enExample)
BG (1) BG65088B1 (enExample)
BR (1) BR9909488B1 (enExample)
CA (1) CA2327468C (enExample)
CY (1) CY1106988T1 (enExample)
CZ (1) CZ301083B6 (enExample)
DE (1) DE69936845T2 (enExample)
DK (1) DK1067933T3 (enExample)
ES (1) ES2292237T3 (enExample)
HU (1) HUP0104273A3 (enExample)
IL (2) IL138856A0 (enExample)
MX (1) MXPA00009840A (enExample)
NO (1) NO328147B1 (enExample)
NZ (1) NZ507350A (enExample)
PL (1) PL196809B1 (enExample)
PT (1) PT1067933E (enExample)
RU (1) RU2217432C2 (enExample)
SK (1) SK285669B6 (enExample)
TR (1) TR200002921T2 (enExample)
UA (1) UA59439C2 (enExample)
WO (1) WO1999051238A1 (enExample)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5985876A (en) * 1997-04-15 1999-11-16 Univ Illinois Nucleophile substituted ecteinascidins and N-oxide ecteinascidins
CN1195514C (zh) * 1998-05-11 2005-04-06 法马马有限公司 海鞘素 743的代谢物
MY164077A (en) * 1999-05-13 2017-11-30 Pharma Mar Sa Compositions and uses of et743 for treating cancer
MY130271A (en) 1999-05-14 2007-06-29 Pharma Mar Sa Hemisynthetic method and new compounds
EP1254140A4 (en) 2000-01-19 2003-03-12 Univ Columbia SAFRAMYCIN-ECTEINASCIDIN SERIES COMPOUNDS, USES AND SYNTHESIS
US7919493B2 (en) * 2000-04-12 2011-04-05 Pharma Mar, S.A. Anititumoral ecteinascidin derivatives
MXPA02011319A (es) 2000-05-15 2003-06-06 Pharma Mar Sa Analogos antitumorales de ecteinascidina 743.
EP1339713A2 (en) 2000-11-03 2003-09-03 President And Fellows Of Harvard College Saframycins, analogues and uses thereof
US20040108086A1 (en) * 2000-11-06 2004-06-10 Naoto Takahashi Effective antitumor treatments
GB0117402D0 (en) * 2001-07-17 2001-09-05 Pharma Mar Sa New antitumoral derivatives of et-743
GB0119243D0 (en) 2001-08-07 2001-10-03 Pharma Mar Sa Antitumoral analogs of ET-743
GB0202544D0 (en) * 2002-02-04 2002-03-20 Pharma Mar Sa The synthesis of naturally occuring ecteinascidins and related compounds
GB0312407D0 (en) * 2003-05-29 2003-07-02 Pharma Mar Sau Treatment
GB0324201D0 (en) * 2003-10-15 2003-11-19 Pharma Mar Sau Improved antitumoral combinations
SI1689404T1 (sl) * 2003-11-13 2009-02-28 Pharma Mar Sau Kombinacija et-743 s 5-fluorouracil pro zdravili za zdravljenje raka
US20080255132A1 (en) * 2003-11-14 2008-10-16 Eric Rowinsky Combination Therapy Comprising the Use of Et-743 and Paclitaxel for Treating Cancer
GB0326486D0 (en) * 2003-11-14 2003-12-17 Pharma Mar Sau Combination treatment
US20080293725A1 (en) * 2004-07-09 2008-11-27 Rafael Rosell Costa Prognostic Molecular Markers
JP2008514688A (ja) * 2004-09-29 2008-05-08 ファルマ・マル・エス・アー， ソシエダッド・ユニペルソナル 抗炎症剤としてのエクテイナシジン化合物
HRP20090345T1 (en) * 2004-10-26 2009-08-31 Pharma Mar S.A. Pegylated liposomal doxorubicin in combination with ecteinescidin 743
RS50510B (sr) 2004-10-29 2010-03-02 Pharma Mar S.A., Sociedad Unipersonal Formulacije koje sadrže ekteinascidin i disaharid
GB0522082D0 (en) * 2005-10-31 2005-12-07 Pharma Mar Sa Formulations
CN100355775C (zh) * 2006-01-20 2007-12-19 南方医科大学 一种海鞘多肽及其制备方法
US20100267732A1 (en) * 2007-10-19 2010-10-21 Pharma Mar, S.A. Prognostic Molecular Markers for ET-743 Treatment
KR102452022B1 (ko) 2010-11-12 2022-10-06 파르마 마르 에스.에이. 항종양 알칼로이드를 이용한 병용요법
JP2019504061A (ja) * 2016-02-04 2019-02-14 ジエンス ヘンルイ メデイシンカンパニー リミテッドＪｉａｎｇｓｕ Ｈｅｎｇｒｕｉ Ｍｅｄｉｃｉｎｅ Ｃｏ．，Ｌｔｄ． トラベクテジンの注射可能な胃腸外用医薬組成物及びその製造方法
JOP20190254A1 (ar) 2017-04-27 2019-10-27 Pharma Mar Sa مركبات مضادة للأورام
PH12022551216A1 (en) 2019-11-21 2023-07-17 Pharma Mar Sa Methods of treating small cell lung cancer with lurbinectedin formulations

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5089273A (en) * 1986-06-09 1992-02-18 Board Of Trustees Of The University Of Illinois Ecteinascidins 729, 743, 745, 759A, 759B and 770
US5149804A (en) * 1990-11-30 1992-09-22 The Board Of Trustees Of The University Of Illinois Ecteinascidins 736 and 722
US5256663A (en) * 1986-06-09 1993-10-26 The Board Of Trustees Of The University Of Illinois Compositions comprising ecteinascidins and a method of treating herpes simplex virus infections therewith
TW221441B (enExample) * 1991-01-25 1994-03-01 Taiho Pharmaceutical Co Ltd
US5440055A (en) * 1993-03-12 1995-08-08 Aphios Corporation Method and apparatus for extracting taxol from source materials
US5478932A (en) * 1993-12-02 1995-12-26 The Board Of Trustees Of The University Of Illinois Ecteinascidins
US5721362A (en) * 1996-09-18 1998-02-24 President And Fellows Of Harvard College Process for producing ecteinascidin compounds

Also Published As

Publication number Publication date
DE69936845T2 (de) 2008-05-08
JP2002510633A (ja) 2002-04-09
KR100603219B1 (ko) 2006-07-20
EP1067933A4 (en) 2002-12-18
WO1999051238A1 (en) 1999-10-14
SK285669B6 (sk) 2007-06-07
EP1067933A1 (en) 2001-01-17
US6124293A (en) 2000-09-26
ES2292237T3 (es) 2008-03-01
CA2327468C (en) 2008-05-06
HUP0104273A3 (en) 2003-12-29
CA2327468A1 (en) 1999-10-14
CZ301083B6 (cs) 2009-11-04
EP1876180A2 (en) 2008-01-09
RU2000128058A (ru) 2004-02-20
CN1304309A (zh) 2001-07-18
RU2217432C2 (ru) 2003-11-27
WO1999051238A9 (en) 2000-01-27
UA59439C2 (uk) 2003-09-15
PT1067933E (pt) 2007-11-15
NO20004978D0 (no) 2000-10-03
DE69936845D1 (de) 2007-09-27
NZ507350A (en) 2003-03-28
EP1876180A3 (en) 2009-12-16
BR9909488B1 (pt) 2011-02-08
AU3471399A (en) 1999-10-25
AU758100B2 (en) 2003-03-13
NO328147B1 (no) 2009-12-21
CN1157189C (zh) 2004-07-14
SK15012000A3 (sk) 2001-08-06
CZ20003650A3 (en) 2001-06-13
IL138856A0 (en) 2001-10-31
HK1033651A1 (en) 2001-09-14
MXPA00009840A (es) 2002-04-24
NO20004978L (no) 2000-12-05
HUP0104273A2 (hu) 2002-03-28
PL343439A1 (en) 2001-08-13
PL196809B1 (pl) 2008-02-29
IL138856A (en) 2007-07-24
DK1067933T3 (da) 2007-12-27
KR20010074474A (ko) 2001-08-04
BR9909488A (pt) 2000-12-26
CY1106988T1 (el) 2012-09-26
EP1067933B1 (en) 2007-08-15
BG65088B1 (bg) 2007-02-28
ATE370148T1 (de) 2007-09-15
TR200002921T2 (tr) 2001-02-21
BG104902A (en) 2001-07-31

Similar Documents

Publication Publication Date Title
JP4443043B2 (ja) 半合成エクテイナシジン
JP2002525296A (ja) エクテイナシジン−７４３の合成類似体
JP2005501093A (ja) 抗腫瘍類似体
JPH02111772A (ja) β―カルボリン類、ベンゾフラン類似体及びベンゾチオフェン類似体並びにこれらの調剤上許容される酸付加塩、β―カルボリン類、ベンゾフラン類似体及びベンゾチオフェン類似体を製造する方法、静細胞特性を有する組成物、腫瘍の治療方法
HU230918B1 (hu) Tumorellenes ekteinaszcidinszármazékok
US20040127709A1 (en) Compounds of the saframycin-ecteinascidin series, uses, and synthesis thereof
US4609494A (en) 5-acetyl-3,4,5,6-tetrahydro-4-oxo-2,6-methano-2H-1,3,5-benzothiazocine(benzodiazocine)-11-carboxylates useful as calcium channel blockers
IL96643A (en) 3 '- Dahmino -'S) - 2 ") - 3 (- Methoxy - 4" - Morpholinyl (-Docsorovicine chirley, its preparation and pharmaceutical preparations containing it
EA014689B1 (ru) Новые соединения - аналоги камптотецина, способ их получения и фармацевтические композиции, которые их содержат
JPH11502871A (ja) 六環式カンプトテシン同族体およびその製造方法
JPH08509740A (ja) カンプトテシンの水溶性誘導体
EP1377588B1 (en) 4-beta-1''-[(2''-(substituted benzoyl)anilino] podophyllotoxin analogues useful as anticancer agents
US4748251A (en) 7-n-aminomethylenemitomycin derivative
HK1033651B (en) Semi-synthetic ecteinascidins
EP1885364B1 (en) Halogenated quindoline dimers for the treatment of cancer
JPH08208653A (ja) アクリルアミド誘導体及びその製造方法
JPH0834788A (ja) ピロロベンゾカルバゾール誘導体及びその製造方法
JPH08151379A (ja) ビス（ピロロインドール）誘導体及びその製造方法
JPS6241666B2 (enExample)

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20060328

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20060328

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20090904

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20091201

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20091222

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20100112

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20130122

Year of fee payment: 3

LAPS Cancellation because of no payment of annual fees